A lung cancer drug shrank brain tumors in 70% of assessed patients.
ORIC Pharmaceuticals presented data showing its lung cancer drug, enozertinib, shrank brain tumors in 70% of assessed patients with EGFR atypical mutations. The company plans to start a global Phase 3 trial in 1H 2027, with enrollment including patients with untreated brain metastases. Enozertinib showed a favorable safety profile and meaningful systemic and intracranial antitumor activity.
How this was made
The 30-second read
Why it matters
The disclosed Phase 1b results provide the first robust intracranial efficacy data for enozertinib, positioning ORIC for a potential accelerated approval pathway.
Market read
First‑time release of compelling trial data likely triggers short‑term price movement and informs longer‑term valuation of ORIC and its peers.
What to watch
The trial size and long‑term survival data remain unknown; market may overprice short‑term response rates.
Background
ORIC Pharmaceuticals is a clinical‑stage oncology company developing enozertinib, a brain‑penetrant EGFR inhibitor, and rinzimetostat for prostate cancer.
Ticker impact
ORIC presented new Phase 1b data showing 70% intracranial response in EGFR‑atypical NSCLC patients and announced a Redwood‑1 Phase 3 trial for 1H 2027.
potential upside as investors price in the best‑in‑class efficacy signals
First disclosure of compelling intracranial response rates and a clear regulatory path creates fresh buying interest.
Market effects
Strengthens the EGFR‑atypical NSCLC niche and may boost peer biotech valuations.
US biotech sector could see modest gains on the news.
Highlights progress in brain‑penetrant oncology therapies, relevant to global oncology investors.
Counterpoint
If Phase 3 enrollment delays or safety issues emerge, the initial hype could reverse.
Key entities
- companyORIC Pharmaceuticals, Inc.
Clinical‑stage biotech developing enozertinib and rinzimetostat.
- drugEnozertinib
Brain‑penetrant EGFR inhibitor showing 70% intracranial ORR in early data.
